What is the prevalence of Maple syrup urine disease?

Maple syrup urine disease (MSUD) is a rare metabolic disorder with an estimated global incidence of approximately 1 in 185,000 live births, though this varies significantly by population. It is considered an ultra-rare condition that affects males and females equally, typically presenting in the neonatal period, though milder, late-onset forms also exist.

How common is Maple syrup urine disease globally?

Maple syrup urine disease is classified as an ultra-rare genetic disorder. While the global incidence is often cited as 1 in 185,000, this number is an estimate based on newborn screening programs and clinical registries. Because Maple syrup urine disease can be fatal if not managed immediately, it is frequently included in expanded newborn screening panels, which has helped improve the accuracy of these prevalence figures. However, true prevalence remains difficult to determine due to the potential for underdiagnosis in regions lacking robust metabolic screening infrastructure.

Are there specific populations more affected by Maple syrup urine disease?

The prevalence of Maple syrup urine disease is not uniform across all ethnic groups. A notable epidemiological feature is the significantly higher incidence within the Old Order Mennonite population in Pennsylvania, where the condition occurs in approximately 1 in 176 live births due to a founder effect. This demonstrates how genetic isolation can drastically shift the frequency of Maple syrup urine disease compared to the general population, where the condition remains exceptionally rare.

What are the demographic and onset patterns of the condition?

Maple syrup urine disease affects both males and females with equal frequency, as it follows an autosomal recessive inheritance pattern. Regarding age of onset, the clinical presentation is categorized by the severity of the enzyme deficiency:

• Classic MSUD: Typically presents within the first few days of life with severe symptoms including poor feeding, lethargy, and the characteristic sweet-smelling urine.


• Intermediate and Intermittent MSUD: These forms may present later in infancy, childhood, or even adulthood, often triggered by metabolic stress, illness, or high protein intake.


• Thiamine-responsive MSUD: A rare variant where symptoms may be managed or mitigated through high-dose thiamine supplementation.

Why is accurate data for Maple syrup urine disease challenging to obtain?

Determining the exact number of people living with Maple syrup urine disease is complicated by several factors. Historical underdiagnosis likely led to lower reported numbers before the advent of tandem mass spectrometry in newborn screening. Additionally, because Maple syrup urine disease requires lifelong specialized dietary management, patients who are diagnosed late or who experience complications may be lost to follow-up, affecting registry data. At DiseaseMaps.org, we have seen 82 people join our community to share their experiences, providing a vital real-world perspective that complements clinical statistics and highlights the ongoing needs of those living with this rare condition.

Next steps

• Consult a metabolic specialist or a clinical geneticist to discuss screening and management protocols.


• Connect with the 82 members of the DiseaseMaps.org community to share experiences and coping strategies.


• Review resources from organizations like the MSUD Family Support Group for guidance on dietary management and clinical updates.


• Ensure your family members are aware of carrier testing options if you or a relative have been diagnosed with Maple syrup urine disease.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Maple syrup urine disease overview.


• Orphanet: Prevalence and incidence of rare metabolic diseases (ORPHA:565).


• OMIM (Online Mendelian Inheritance in Man): Entry #248600 (Maple syrup urine disease).


• MSUD Family Support Group: Patient advocacy and educational resources.